← Library
Sermorelin
FDA ApprovedSince 1990
Also known as Geref
Function
Primary
Growth Hormone Deficiency (pediatric)
Secondary
Adult GH optimization (compounded, off-label)
Mechanism
GHRH receptor agonist — stimulates pituitary to secrete endogenous GH; physiological pulsatile release preserved.
Evidence
Clinical RCT (Phase III)
Research
Phase III pediatric GH trials
Dosing
Range
0.2–0.3 mg/day
Frequency
Daily at bedtime
Route
Subcutaneous
Cycling
Commonly 5-day-on / 2-day-off; or 3 months on, 1 month off (off-label).
Benefits
- ·Preserves physiologic GH pulsatility
- ·Improves sleep quality
- ·Lean body mass support (off-label)
Risks
- ·Flushing
- ·Injection site reactions
- ·Headache
- ·Theoretical IGF-1 elevation
Contraindications
- ·Active malignancy
- ·Hypersensitivity to GHRH
- ·Pregnancy
Regulatory
FDA-Approved Rx (discontinued); Compounded Rx available
Functional Groups
Cited Works
- Serono. Geref (sermorelin) Prescribing Information (discontinued 2008).